
Gilead Expands Global Access to Lenacapavir With New HIV Prevention Partnership
On July 9, 2025, Gilead Sciences, Inc announced a strategic partnership with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply up to 2 million people in low and lower-middle income countries (LLMICs) with yeztugo, (lenacapavir) a long- …